Perfusion Magnetic Resonance as a Biomarker for Sorafenib-Treated Advanced Hepatocellular Carcinoma: A Pilot Study

Background: Sorafenib is the currently recommended therapy in patients with advanced hepatocellular carcinoma (HCC). Among the several biomarkers available for the evaluation of the therapeutic response and prognosis, there is perfusion magnetic resonance imaging (p-MRI) that, through measurement of...

ver descrição completa

Detalhes bibliográficos
Autor principal: Campos,Marta (author)
Outros Autores: Candelária,Isabel (author), Papanikolaou,Nickolas (author), Simão,Adélia (author), Ferreira,Carlos (author), Manikis,Georgios C. (author), Caseiro-Alves,Filipe (author)
Formato: article
Idioma:eng
Publicado em: 2019
Assuntos:
Hepatocellular carcinoma
Sorafenib
Angiogenesis
Magnetic resonance imaging perfusion
ktrans
Tumor markers
Texto completo:http://scielo.pt/scielo.php?script=sci_arttext&pid=S2341-45452019000400006
País:Portugal
Oai:oai:scielo:S2341-45452019000400006

Texto Completo

http://scielo.pt/scielo.php?script=sci_arttext&pid=S2341-45452019000400006

Registos relacionados